Iodixanol in paediatric excretory urography: efficiency and safety compared to iohexol.
BACKGROUND
Iodixanol (Visipaque, Nycomed Imaging AS, Oslo, Norway) is a new non-ionic and isotonic X-ray contrast medium.


OBJECTIVE
To assess its safety and efficacy for paediatric excretory urography.


METHODS
A three-centre trial in which 72 patients were randomised into three parallel groups: iodixanol 270 mgI/ml, iodixanol 320 mgI/ml and iohexol 300 mgI/ml (Omnipaque, Nycomed Imaging, Oslo, Norway). Doses ranging from 1 to 3 ml/kg never exceeded 50 ml. Pulse rate and blood pressure were recorded before, during, and after the examination. Adverse events, including injection associated discomfort, were recorded during and up to 24 h after the examination. The diagnostic quality of the urograms was assessed on a four-level scale.


RESULTS
No serious adverse event occurred in any of the three groups. One patient who was given iodixanol 270 mgI/ml, three who received iodixanol 320 mgI/ml, and one who received iohexol 300 mgI/ml experienced transient adverse events. More than 80 % of the urograms in all three groups were rated "good" or "excellent".


CONCLUSIONS
Iodixanol, either 270 mgI/ml or 320 mgI/ml, is well tolerated and efficacious for excretory urography in children.
Dacher
J
J
Department of Paediatric Radiology, Hôpital Charles Nicolle, F-76031, Rouen, France.
Sirinelli
D
D
Boscq
M
M
Hassan
M
M
Garel
C
C
Chateil
J F
JF
Amar
C
C
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003287:Contrast Media / Q000008:administration & dosage; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007472:Iohexol / Q000008:administration & dosage; D008297:Male; D011897:Random Allocation; D014283:Triiodobenzoic Acids / Q000008:administration & dosage; D014567:Urography
D003287:Contrast Media; D014283:Triiodobenzoic Acids; D007472:Iohexol; C044834:iodixanol